Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) disclosed that it has inked a definitive agreement for the purchase of Checkmate...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have confirmed that European Commission has extended the marketing authorization for Dupixent (dupilumab) in the...
Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) have jointly created Dupilumab under a global collaboration agreement. The European Medicines Agency's Committee for Medicinal Products...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Sanofi (NASDAQ: SNY) revealed the findings of the Phase III trial evaluating the effectiveness of Dupixent in babies and...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) revealed on Thursday that FDA has awarded the authorization to Dupixent as an add-on cure...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is preparing to deliver 12, 000 antibody treatment to the Czech Republic before the authorization of the EU. The...
